Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

NCT01369433 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01369433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01369433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Not applicable
Overall status
Terminated
Start date
June 30, 2010
Completion date
October 31, 2015
Enrollment
225 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors